In case these assumptions are incorrect and RRS has no effect on ovarian cancer incidence, ovarian cancer risk will increase with a maximum of 2.3% points for BRCA1 and 1.2% point for BRCA2-PV carriers, respectively, depending on age at surgery [51]. This evidence concerns the gene BRCA1 and ovarian cancer.